Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 1997

View Archived Issues

Xenova: Q3 1997 highlights

SmithKline Beecham: Q3 1997 highlights

Nefadar: new antidepressant introduced in Germany

Extended-release Effexor introduced in U.S. for depression

rhBMP-2 efficacy in dental reconstruction demonstrated

Scios and DuPont Merck collaborate on Alzheimer's disease research

Positive phase I/II results reported for adenoviral p53 gene therapy

Synergistic antihypertensive activity of Ang II antagonist/ACE inhibitor combination in SHR

Results from Leuvectin trial in kidney cancer patients reported

Preliminary results reported for IL-2 gene therapy in GI cancer

NINDS study links herpesvirus strain to MS

ImmuLogic restructures its operations

Sertoli and Carolinas Medical Center collaborate to develop novel diabetes therapy

ProLease hGH slated to enter phase III

Milestone reached in antiinfectives alliance

New agents for heart disease prepared by Dainippon Ink & Chemicals

Roussel Uclaf discloses integrin antagonists for bone disorders

Takeda develops potassium channel openers for cardiovascular indications

PTK inhibitors for bone disorders from Novartis

Arzneimittelwerk Dresden prepares new 5-LO inhibitors

JT licenses new oral antiinflammatory agent to R.W. Johnson

NDA filed in U.S. for Otsuka antiplatelet agent

First marketing approval granted for Neumega

Subset of stroke patients shows neurological improvement after phenylephrine-induced hypertension

Expanded use approved for ReoPro in Europe

Cardiotoxicity of SM-5887 and doxorubicin compared in rabbits

Fedotozine efficacy in functional dyspepsia established

Preclinical pharmacokinetics, antitumor activity and toxicity of CI-994

Electroporation for gene delivery into tumor cells: in vivo results

Forest files for FDA approval of Synapton

Fujirebio, Nippon Chemiphar to codevelop antiasthma drug

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...